SAN DIEGO, Calif., January 23, 2026 – Bloom Science, Inc., a clinical-stage biotechnology company developing next-generation live biotherapeutic medicines targeting the gut-brain axis, today announced that members of its executive leadership team will participate in the upcoming Keystone Symposia on Obesity Therapeutics and the Microbiome Revolution Symposium hosted by CE-Ventures in Dubai.

These scientific engagements will provide Bloom an opportunity to share its differentiated approach to metabolic and neurological disease, centered on microbiome-driven modulation of the gut-brain axis.

At the Keystone Symposia on Obesity Therapeutics, Bloom plans to engage with leading academic researchers, clinicians, and biotechnology innovators to discuss emerging advances in obesity biology and translational medicine. The company intends to highlight its lead clinical-stage program, BL-001, an orally delivered live biotherapeutic product designed to replicate key therapeutic mechanisms of ketogenic biology through gut-derived metabolic signaling.

“Obesity is a complex, multi-pathway disease that requires innovative therapeutic strategies,” said Christopher Reyes, PhD, Chief Executive Officer of Bloom Science. “We look forward to engaging with leaders in metabolic science and discussing how our live biotherapeutic approach may offer a differentiated path forward.”

At the Microbiome Revolution Symposium in Dubai, Dr. Reyes is scheduled to present Bloom’s platform strategy and clinical progress to an international audience of microbiome researchers, healthcare investors, and industry leaders. The symposium will focus on the growing role of microbiome science in transforming therapeutic development.

Bloom intends to showcase its proprietary IrisRx™ discovery platform and discuss how its programs are designed to influence systemic metabolism and neurological function through the gut-brain axis. The company will also provide updates on BL-001, which demonstrated statistically significant placebo-adjusted weight loss and durable metabolic effects in a Phase 1 clinical trial and is advancing toward Phase 2 development in obesity and rare epilepsies, including Dravet syndrome.

“These forums represent important opportunities to connect with the global scientific and investment communities,” added Dr. Reyes. “We believe microbiome-driven therapeutics are poised to redefine treatment paradigms across metabolic and neurological disease.”

Bloom management will be available for meetings during both events.

About Bloom Science
Bloom Science is a clinical-stage biotechnology company developing live biotherapeutic medicines targeting the gut-brain axis. Powered by its proprietary IrisRx™ discovery platform, Bloom designs therapeutics that modulate metabolic and neurological pathways to address complex diseases including obesity and rare epilepsies. Bloom is headquartered in San Diego, California.

SAN DIEGO, Calif., January 8, 2026 – Bloom Science, Inc., a clinical-stage biotechnology company developing next-generation live biotherapeutic medicines targeting the gut-brain axis, today announced that members of its executive leadership team will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and the upcoming 9th Annual Sachs Neuroscience Innovation Forum.

Bloom’s leadership team will meet with investors, strategic partners, and industry leaders during J.P. Morgan Healthcare Conference week, and will engage with neuroscience-focused investors and innovators at the Sachs Neuroscience Innovation Forum, which convenes global stakeholders advancing therapies for neurological and neurodegenerative disorders.

At these meetings, Bloom intends to highlight recent clinical progress from its lead program, BL-001, an orally delivered live biotherapeutic product designed to replicate key mechanisms of ketogenic biology. Phase 1 data demonstrated statistically significant placebo-adjusted weight loss and durable metabolic effects, supporting the program’s advancement toward Phase 2 development in obesity and rare epilepsies, including Dravet syndrome.

“Healthcare Conference week provides an important opportunity to engage both the broader investment community and specialized neuroscience investors,” said Christopher Reyes, PhD, Chief Executive Officer of Bloom Science. “We look forward to discussing our differentiated gut-brain axis approach and our plans to advance BL-001 into its next stage of clinical development.”

The Sachs Neuroscience Innovation Forum brings together leading companies, investors, and academic experts focused on advancing therapies across neurological diseases, including epilepsy, neurodegeneration, and psychiatric disorders. Bloom’s participation reflects its commitment to addressing complex metabolic and neurological conditions through a novel live biotherapeutic modality.

Bloom management will be available for scheduled one-on-one meetings during both conferences.

About Bloom Science
Bloom Science is a clinical-stage biotechnology company developing live biotherapeutic medicines targeting the gut-brain axis. Powered by its proprietary IrisRx™ discovery platform, Bloom designs therapeutics that modulate metabolic and neurological pathways to address complex diseases including obesity and rare epilepsies. Bloom is headquartered in San Diego, California.